Plain-English translation of NCT07625423 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a combination of two treatments for people with advanced head and neck cancer that has come back or spread after platinum-based chemotherapy. One treatment is EDS01, a new therapy that is injected directly into the tumor to help stop blood vessel growth in cancer cells. The other is toripalimab, an immunotherapy drug given by infusion that helps your immune system fight cancer. Researchers want to see if these two treatments work better together and are safe to use.
When head and neck cancer comes back or spreads after standard chemotherapy, patients have very few good treatment options left. This medication aims to attack tumors in a new way—by cutting off their blood supply locally—while the immunotherapy works to wake up the immune system, potentially offering hope to patients with limited choices.
You likely qualify if…
You likely don't qualify if…
You would receive the new injection directly into your tumor on two days (Day 0 and Day 7), and then an infusion of the immunotherapy drug on Day 1 of each 21-day treatment cycle. The study continues for up to 4 cycles (about 3 months total) unless your cancer gets worse or side effects become too severe. During the trial, you will have regular blood tests, physical exams, and imaging scans to check how the tumors are responding and monitor for any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China